Abstract
Two spontaneous mouse leukemias were adapted to culture. In agreement with most reported observations on spontaneous tumors, injection of irradiated cells of the malignant culture cell lines failed to protect mice against these leukemias. These cell lines were treated in vitro with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine and stable immunogenic variants (tum-) were obtained, that failed to form progressive tumors in syngeneic CBA/Ht mice. Mice that had rejected tum- variants showed a significant degree of resistance to challenge not only with the original malignant cell line but also with the original transplantable tumor. No protection was observed against syngeneic tumor cells other than those of the parental tumor. These results indicate that these two spontaneous leukemias carry a specific transplantation antigen that can be the target of a rejection response by syngeneic mice. In confirmation of this, we found that lymphocytes of CBA/Ht mice that had rejected tum- variants could be restimulated in vitro so as to develop a cytolytic activity directed against an antigen that was specific for the original tumor cell line.
Full Text
The Full Text of this article is available as a PDF (595.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boon T., Kellermann O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A. 1977 Jan;74(1):272–275. doi: 10.1073/pnas.74.1.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Boon T., Van Pel A. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci U S A. 1978 Mar;75(3):1519–1523. doi: 10.1073/pnas.75.3.1519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Boon T., Van Snick J., Van Pel A., Uyttenhove C., Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med. 1980 Nov 1;152(5):1184–1193. doi: 10.1084/jem.152.5.1184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Frost P., Kerbel R. S., Bauer E., Tartamella-Biondo R., Cefalu W. Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res. 1983 Jan;43(1):125–132. [PubMed] [Google Scholar]
- Hewitt H. B., Blake E. R. Stability of transplanted murine tumour systems after storage of cells at -196 degrees C for up to 13 years. Br J Cancer. 1978 May;37(5):718–722. doi: 10.1038/bjc.1978.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hewitt H. B., Blake E. R., Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;33(3):241–259. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- KLEIN E., KLEIN G. ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT. J Natl Cancer Inst. 1964 Mar;32:547–568. [PubMed] [Google Scholar]
- KLEIN G., SJOGREN H. O., KLEIN E., HELLSTROM K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960 Dec;20:1561–1572. [PubMed] [Google Scholar]
- Klein G., Klein E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A. 1977 May;74(5):2121–2125. doi: 10.1073/pnas.74.5.2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kobayashi H. Viral xenogenization of intact tumor cells. Adv Cancer Res. 1979;30:279–299. doi: 10.1016/s0065-230x(08)60899-4. [DOI] [PubMed] [Google Scholar]
- Maryanski J. L., Van Snick J., Cerottini J. C., Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol. 1982 May;12(5):401–406. doi: 10.1002/eji.1830120508. [DOI] [PubMed] [Google Scholar]
- Middle J. G., Embleton M. J. Naturally arising tumors of the inbred WAB/Not rat strain. II. Immunogenicity of transplanted tumors. J Natl Cancer Inst. 1981 Sep;67(3):637–643. [PubMed] [Google Scholar]
- Mitchison N. A. Immunologic approach to cancer. Transplant Proc. 1970 Mar;2(1):92–103. [PubMed] [Google Scholar]
- PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
- Uyttenhove C., Van Snick J., Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med. 1980 Nov 1;152(5):1175–1183. doi: 10.1084/jem.152.5.1175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van Pel A., Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4718–4722. doi: 10.1073/pnas.79.15.4718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van Pel A., Georlette M., Boon T. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5282–5285. doi: 10.1073/pnas.76.10.5282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vessière F., Georlette M., Warnier G., Leclerc J. C., Van Pel A., Boon T. Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes. Eur J Cancer Clin Oncol. 1982 Sep;18(9):867–874. doi: 10.1016/0277-5379(82)90197-3. [DOI] [PubMed] [Google Scholar]